A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan.

"Declarations Conflict of interestYucherng Chen, Taeko Katayose, Soshi Nagaoka, Yongzhe Piao, and Hiroya Asou are employees and minor shareholders of Eli Lilly Japan K.K., Kobe, Japan. Kensei Yamaguchi reports grants and personal fees from Eli Lilly Japan K.K. during the conduct of the study; and grants and personal fees from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Sanofi; grants from Sumitomo Dainippon Pharma Co., Ltd, Boehringer Ingelheim, Gilead Sciences, Inc., and Yakult Honsha Co., Ltd; and personal fees from Merck Serono Co., Ltd, Takeda Pharmaceutical Co., Ltd, Bristol-Myers Squibb, and Bayer, outside the submitted work. Ethical approvalAs a non-interventional post-marketing study, this work was conducted in compliance with the Good Post-marketing Study Practice in Japan. This article does not contain any interventional studies with human or animal subjects performed by any of the authors. Conflict of interest Yucherng Chen, Taeko Katayose, Soshi Nagaoka, Yongzhe Piao, and Hiroya Asou are employees and minor shareholders of Eli Lilly Japan K.K., Kobe, Japan. Kensei Yamaguchi reports grants and personal fees from Eli Lilly Japan K.K. during the conduct of the study; and grants and personal fees from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Sanofi; grants from Sumitomo Dainippon Pharma Co., Ltd, Boehringer Ingelheim, Gilead Sciences, Inc., and Yakult Honsha Co., Ltd; and personal fees from Merck Serono Co., Ltd, Takeda Pharmaceutical Co., Ltd, Bristol-Myers Squibb, and Bayer, outside the submitted work."

"This work was supported by Eli Lilly Japan K.K., Kobe, Japan. Medical writing assistance (Kaye L. Stenvers, PhD) and editorial assistance (Antonia Baldo, Angela Lorio, and Cynthia Abbott) were provided by Syneos Health and funded by Eli Lilly Japan K.K."